http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3145506-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27caf332c6f22f41fbe55132a8c2f019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1000c9e819bcdb940ee9c9d1bc86f355
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-007
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00
filingDate 2015-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90ec4206491362cd1e75ecdbc938741a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_199dd414813e3b3a2817d6820452d594
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7241167fbc16558764464e8b2c3806a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2984bf61e91fecc2fe6bfeeeb16394dd
publicationDate 2017-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-3145506-A1
titleOfInvention Combination of xenon and an antioxidant to control a parkinson's disease-type neurodegenerative disease
abstract The invention relates to a drug combination including xenon gas and at least one antioxidant, in liquid or solid form, for use in treating, slowing, or preventing neurological damage following a neurodegenerative disease in a human being. Preferably, the xenon content is 10% to 80% by volume. Also, the antioxidant is preferably vitamin E, a vitamin E analog, or a vitamin E derivative. The neurodegenerative disease is Parkinson's disease or a disease related to Parkinson's disease.
priorityDate 2014-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226449503
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399686
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10255
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399605
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3868
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226851902
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID681
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406072
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14985
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1221
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6083
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395359
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2118
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227373505
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1515192
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397217
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID40634
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395461

Total number of triples: 46.